跳至主要内容
临床试验/NCT01484288
NCT01484288已完成不适用

Baroreflex Activation Therapy in Heart Failure

CVRx, Inc.1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2011年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
CVRx, Inc.
入组人数
12
试验地点
1
主要终点
Changes in Sympathetic Nervous System Activity (MSNA Bursts/Min)

研究概览

简要总结

The purpose of this clinical investigation is to evaluate the efficacy and safety of the CVRx Barostim Neo System in the treatment of patients with heart failure.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age at least 21 years
  • Symptomatic heart failure despite optimal, stable pharmacological therapy for at least 4 weeks

排除标准

  • Significant carotid plaque or stenosis
  • Known or suspected baroreflex failure or autonomic neuropathy
  • Myocardial infarction, unstable angina, syncope, cerebral vascular accident, SCD, or received defibrillation therapy within the past 3 months
  • Heart failure secondary to a reversible condition

结局指标

主要结局

Changes in Sympathetic Nervous System Activity (MSNA Bursts/Min)

时间窗: 6 months

Change in muscle sympathetic nerve activity (MSNA) in bursts/min at 6 months compared to baseline

Changes in Sympathetic Nervous System Activity (MSNA Bursts/100 Heartbeats)

时间窗: 6 months

Changes in Muscle Sympathetic Nerve Activity (bursts/100 heartbeats) at 6 months compared to baseline

次要结局

  • Change in Diastolic Blood Pressure(6 months)
  • Change in Heart Rate(6 months)
  • Change in Six-Minute Hall Walk(6 months)
  • Change in Left Ventricular Ejection Fraction (LVEF)(Six months)
  • New York Heart Association (NYHA) Class(Six months)
  • Change in Systolic Blood Pressure(6 months)
  • Change in Quality of Life (Minnesota Living With Heart Failure Questionnaire)(Six months)

研究者

发起方
CVRx, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验